Conference data: Andromeda Phase III RCT of subcutaneous daratumumab combination in untreated light chain (AL) amyloidosis

RCT (n=388) found that subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher haematological complete response rate vs CyBorD (53% vs. 18%; OR 5.1; 95% CI 3.2-8.2; P<0.0001).

Biospace Inc.